Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch
January 30th, 2019
Exclusive, News, Top Story
In Canada, registered medical patients have been able to access cannabis-derived cannabidiol (CBD) oils since 2001, and the government’s move to legalize cannabis in October 2018 opened the adult-use market. According to an article by CBC, the result has been a shortage of medicinal CBD, though opinions vary on exact reasons for the current lack of supply. According to James O’Hara, of the advocacy group Canadians for Fair Access to Medical Marijuana, “It’s actually more than a supply issue. Really, it’s something of a health crisis now. Unfortunately, there are no regulations in place to actually guarantee supply for the medical market.”
The Canadian medical market is only expected to grow, with forecasts calling for more than $2 billion of spending by the end of 2020.
Source: New Frontier Data
On the pharmaceutical front, as science catches up after years of prohibition, research indicates CBD may have a wide array of health benefits. Companies across the globe are advancing drug candidates to address conditions ranging from seizures to inflammation to cancer. The opportunity is tremendous. For example, Epidiolex, the only FDA-approved CBD drug, to treat a small family of rare illnesses, is estimated to generate $625 million in international annual revenue by 2022.
The questions underlying these trends are: Where will all the CBD come from? And more to the point, where will the pure pharmaceutical CBD, manufactured in Health Canada and FDA approved facilities that meet the strictest regulations, come from? Cardiol Therapeutics (TSX: CRDL) is providing these answers with the upcoming launch of its pharmaceutical CBD products, with the capacity to scale manufacturing to metric tonnes per year.
Partnerships Drive Capability
In 2017, Cardiol secured an exclusive agreement with Dalton Pharma Services, which at the time was the one of the very few Health Canada approved and FDA registered companies in Canada licensed to produce pharmaceutical CBD. The program was initially conceived so Cardiol could secure the supply needed to conduct its clinical trial program, with the two companies working together on the formulations required. Following the deal, Dalton’s founder, Peter Pekos, took a seat on Cardiol’s Board of Directors.
Since that initial agreement, the opportunity to manufacture and sell pharmaceutical CBD around the world became clear. Cardiol now has an exclusive global manufacturing agreement with Dalton for the supply of pharmaceutical CBD for commercial introduction.
To further boost capacity, Cardiol has engaged in an exclusive supply agreement with Noramco, a global leader in the development and manufacture of active pharmaceutical ingredients. This agreement covers the Canadian and Mexican markets and gives Cardiol a path to significantly scale its production to metric tonnes of CBD per year.
Canada’s only GMP Manufactured, Pure THC-Free CBD
By partnering with Dalton and Noramco, Cardiol is assured of the highest quality product manufactured in the most advanced and regulated facilities.
Pharmaceutical CBD can provide the material for drug research like Cardiol’s existing program. It can be sold on its own to medical patients in legal jurisdictions. It can also be the primary ingredient in any number of CBD products, ranging from edibles to creams, nutraceuticals to pharmaceuticals.
Cardiol Therapeutics plans on introducing its pharmaceutical CBD line in H2 2019. The company views this as a significant revenue opportunity that will financially support its clinical research. The clinical trial process is long and fraught with pitfalls, but the rewards are vast in terms of revenue potential. In the meantime, Cardiol Therapeutics is distinguishing itself from other researchers by providing a significant but related revenue stream. Stay tuned.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.